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Objectives This study sought to assess the effectiveness of a strategy of using drug-eluting stents
(DES) with a different drug (switch) in patients with DES in-stent restenosis (ISR).
Background Treatment of patients with DES ISR remains a challenge.
Methods The RIBS-III (Restenosis Intra-Stent: Balloon Angioplasty Versus Drug-Eluting Stent) study
was a prospective, multicenter study that aimed to assess results of coronary interventions in pa-
tients with DES ISR. The use of a different DES was the recommended strategy. The main angio-
graphic endpoint was minimal lumen diameter at 9-month follow-up. The main clinical outcome
measure was a composite of cardiac death, myocardial infarction, and target lesion revascularization.
Results This study included 363 consecutive patients with DES ISR from 12 Spanish sites. The different-
DES strategy was used in 274 patients (75%) and alternative therapeutic modalities (no switch) in 89 pa-
tients (25%). Baseline characteristics were similar in the 2 groups, although lesion length was longer in
the switch group. At late angiographic follow-up (77% of eligible patients, median: 278 days) minimal
lumen diameter was larger (1.86  0.7 mm vs. 1.40  0.8 mm, p  0.003) and recurrent restenosis rate
lower (22% vs. 40%, p  0.008) in the different-DES group. At the last clinical follow-up (99% of patients,
median: 771 days), the combined clinical endpoint occurred less frequently (23% vs. 35%, p  0.039) in
the different-DES group. After adjustment using propensity score analyses, restenosis rate (relative risk:
0.41, 95% conﬁdence interval [CI]: 0.21 to 0.80, p  0.01), minimal lumen diameter (difference: 0.41 mm,
95% CI: 0.19 to 0.62, p  0.001), and the event-free survival (hazard ratio: 0.56, 95% CI: 0.33 to 0.96, p 
0.038) remained signiﬁcantly improved in the switch group.
Conclusions In patients with DES ISR, the implantation of a different DES provides superior late
clinical and angiographic results than do alternative interventional modalities. (J Am Coll Cardiol
Intv 2012;5:728–37) © 2012 by the American College of Cardiology Foundation
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729Drug-eluting stents (DES) are widely used due to their
dramatic antirestenosis efficacy (1). However, DES are not
immune to in-stent restenosis (ISR), particularly when used
with off-label indications in complex clinical and angio-
graphic scenarios (2–4). In fact, treatment of DES ISR
represents a growing clinical problem (2–4). Favorable early
experiences have been reported in these patients using
See page 738
several coronary interventions, including conventional bal-
loon angioplasty, cutting balloon angioplasty, bare-metal
stents (BMS), and repeat DES implantation (5–16). How-
ever, most studies suggest that despite satisfactory initial
results, patients with DES ISR have poorer long-term
clinical and angiographic outcomes than those classically
seen in patients with BMS ISR (7,8). Therefore, treatment
of patients with DES ISR remains a technical and clinical
challenge and the intervention of choice for these patients
remains unsettled (2–4).
From a pathophysiological standpoint, the use of a
different DES (“switch” strategy) is highly appealing and has
been previously advocated for patients with DES ISR (11–16).
The concept of drug resistance provides the foundation for this
distinct therapeutic approach (17–19). However, early results
of the switch strategy, mainly coming from observational
studies but also from randomized clinical trials, remain con-
troversial (11–16).
In this large prospective, multicenter study, we sought to
assess the value of a different DES strategy in patients
presenting with DES ISR.
Methods
Patient selection and study design. The RIBS-III (Reste-
osis Intra-Stent: Balloon Angioplasty Versus Drug-
luting Stent Implantation) study was designed as a pro-
pective, multicenter study aimed to assess the results of
oronary interventions in patients with DES ISR (Online
ppendix). Specifically, the study sought to assess the value
f the switch strategy (DES with a different drug) in this
etting. DES with different drugs but within the same
amily (limus) were considered as different DES. However,
s a secondary “exploratory” analysis, the switch to a
ifferent DES “family” (any limus DES to a nonlimus DES
nd vice versa) was also assessed. Inclusion and exclusion
riteria were similar to those used in previous RIBS studies
20,21). Briefly, patients with ISR (50% diameter stenosis
n visual assessment) after DES implantation (any DES
ualified) were eligible if they presented with angina or
ocumented ischemia. In patients in whom the initial DES
as implanted in another center, the original procedural
eport was obtained. When the type or location of the
riginal stent remained unknown, the patient was notncluded in the study. Patients with DES ISR on small
essels (2.0 mm) or very diffuse ISR (32 mm) were
xcluded. Patients with early (4 weeks) DES ISR, those
resenting as an acute myocardial infarction, and those with
ntracoronary thrombus were also excluded (20,21). Patients
ith edge-ISR, affecting the 5-mm coronary segments
djacent to the previous DES, were only included if the
tent border was involved. Where in doubt, the protocol
uggested the use of intravascular ultrasound imaging to
onfirm the involvement of the stent edge. Additional
xclusion criteria were current contraindications to aspirin or
lopidogrel, severe renal failure, and major concomitant sys-
emic diseases potentially interfering with clinical follow-up.
The use of a different DES was the recommended strategy.
owever, patients eventually treated with alternative strategies
at the discretion of local investigators) were also included. The
ain angiographic endpoint was the in-segment minimal lu-
en diameter (MLD) at 9-month
ollow-up as assessed by quanti-
ative coronary angiography.
he main clinical outcome mea-
ure was a composite of cardiac
eath, myocardial infarction,
nd target lesion revasculariza-
ion (TLR).
Twelve university hospitals
rom Spain participated in the
rial (Online Appendix). Data
ollection, management, and
nalysis were performed at the
oordinating center (Clı´nico San
arlos University Hospital, Ma-
rid, Spain). The study was an
nvestigators-driven initiative
nd was conducted under the
uspices of the Working Group
n Interventional Cardiology of
he Spanish Society of Cardiology. All patients gave in-
ormed consent to the procedure. The study was performed
ccording to the provisions of the Declaration of Helsinki
egarding investigations with human subjects. Following
urrent Spanish regulations for prospective multicenter
tudies, the protocol was approved by the Institutional
thics Committee at the coordinating center.
Coronary interventions. All patients were pre-treated with
aspirin and clopidogrel. A loading dose of clopidogrel (300
to 600 mg) was administered to clopidogrel-naive patients
requiring ad hoc interventions. Before interventions, a bolus
of unfractionated heparin (100 mg/kg) was given followed
by subsequent boluses as required to maintain an activated
clotting time 250 s.
The protocol suggested lesion pre-dilation with an under-
sized and relatively short balloon to avoid damaging the
Abbreviations
and Acronyms
BMS  bare-metal stent(s)
CI  confidence interval
DES  drug-eluting stent(s)
HR  hazard ratio
IQR  interquartile range
ISR  in-stent restenosis
MLD  minimal lumen
diameter
PES  paclitaxel-eluting
stent(s)
RR  relative risk
SES  sirolimus-eluting
stent(s)
TLR  target lesion
revascularizationcoronary vessel segment adjacent to the lesion site. Care was
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730taken to prevent balloon slippage phenomena. The importance
of complete lesion coverage to prevent geographic-miss–
related problems was emphasized (21). The use of a final 1.1/1
balloon-to-artery ratio and relatively high pressures (14 bar)
was recommended (21). Special emphasis was made to care-
fully seek, and aggressively treat, underlying underexpanded
stents or residual underexpansion of the new stent. In this
setting, the use of additional noncompliant balloons at high
pressures was recommended. Although the value of intracoro-
nary imaging techniques to assess DES expansion was explic-
itly described in the protocol, the use of these techniques was
not mandated and remained a decision of the local investigators.
Serial serum creatine kinase levels (with myocardial band
determinations when abnormal) and 12-lead electrocardio-
grams were routinely obtained for 24 h. After the procedure,
all patients received aspirin indefinitely and clopidogrel (75
mg/day) for 1 year after repeat DES implantation and for
only 1 month following other interventions.
Follow-up and deﬁnitions. Patients were followed-up at 1
month, 9 months, and 1 year and yearly thereafter. Angio-
graphic follow-up was initially scheduled at 9 months but
was performed earlier if clinically indicated. Case-report
forms were completed at each site by local investigators and
submitted to the coordinating center. Data were reviewed
for completeness and consistency checks were systematically
performed. When required, specific queries were sent back
to the sites. All data were entered into a dedicated, rela-
tional, database specifically designed for the RIBS studies.
All major events were verified against source documenta-
tion. Clinical events (death, myocardial infarction, TLR)
were adjudicated by an independent Clinical Events Com-
mittee that was unaware of the interventional strategy used.
All deaths were considered as cardiac unless a clear noncar-
diac cause could be established. The diagnosis of myocardial
infarction required at least 2 of the following: 1)30 min of
chest pain; 2) creatine kinase rise 2 the upper normal
local value (with abnormal myocardial band fraction); and
3) development of pathological Q waves (21). The protocol
indicated that all repeated interventions during follow-up
had to be clinically justified (i.e., based on symptoms or
objective evidence of ischemia). The Academic Research
Consortium definition was used to assess the presence of
stent thrombosis (22).
Angiographic analysis. Coronary angiograms were centrally
nalyzed at the angiographic core laboratory by trained
ersonnel blinded to treatment allocation (20,21). The
merican College of Cardiology/American Heart Associa-
ion (23) and the Mehran classifications (24) were used to
ualitatively assess lesion morphology. Quantitative coro-
ary angiography was performed with an automatic edge-
etection system (CASS II System, Pie Medical, Maas-
richt, the Netherlands). Selected angiographic views that
voided vessel foreshortening and side-branch overlap were
btained after nitroglycerin administration. The same pro-ections were repeated after intervention and at late follow-
p. In-lesion and in-segment (treated segment plus 5-mm
egments on both sides) analyses were performed (21).
eference vessel diameter, MLD, percentage of diameter
tenosis, late loss, loss index, and net gain were measured.
inary restenosis was defined as 50% diameter stenosis at
ate angiography.
Statistical analysis. Categorical variables were compared
with the chi-square test or Fisher exact test as required.
Continuous data are presented as mean  SD or median
(interquartile range [IQR]) according to data distribution
(Kolmogorov-Smirnov test). The Student t test or the Mann-
Whitney tests were used for the comparison of continuous
variables. Logistic regression analysis and multiple linear re-
gression analysis were used to determine predictors of resteno-
sis and MLD at follow-up, respectively. Kaplan-Meier analy-
ses were performed to estimate event-free survival among
different interventions that were compared with the log-rank
and Breslow tests. Univariate and multivariate Cox regression
analyses were used to determine predictors of events during
follow-up. To avoid potential bias caused by confounding
by indication, propensity score analyses were also per-
formed. Variables selected for the propensity score were
diabetes, time to restenosis, lesion length, vessel diameter
(clinical criteria) and 1 restenosis, baseline MLD, edge-
ISR, calcium, and ostial location (statistical criteria, p  0.2
at the univariate analysis). Most of these variables, in
addition to age, sex, and clinical presentation, were included
in the different multivariate models. The propensity score
was estimated using a multivariable logistic regression
model and entered into the corresponding treatment effect
models as a covariate to adjust for baseline differences. The
C-index (area under the receiver-operating characteristic
curve) was calculated to confirm adequate model fit. Rela-
tive risk [RR] and hazard ratio [HR] (95% confidence
interval [CI]) were determined. The SPSS (version 15,
IBM, Armonk, New York) statistical package was used. A
value of p  0.05 was considered statistically significant.
Results
From July 2004 to October 2009, 363 consecutive patients
with ISR were prospectively enrolled in the study. Most
patients (n  274, 75%) were treated with the recommended
different-DES strategy. However, alternative therapeutic strat-
egies were selected by the local investigator in 89 patients
(25%) (same-DES [n  51], BMS [n  9], balloon angio-
plasty [n 29]) (Fig. 1). A significant number of patients were
treated with limus-family DES (n  225, 67%) or second-
generation DES (n 107, 32%). Table 1 summarizes baseline
clinical and angiographic characteristics of the total patient
cohort and compares results of patients treated with the
different-DES approach and other strategies. Baseline clinical
findings were similar in both groups with a high rate of
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731diabetics. Time to ISR tended to be shorter in the switch
group. Results of the quantitative angiography analysis are
shown in Table 2. In the switch group, lesions were longer and
tended to be more severe. High dilation pressures were used in
both groups. Angiographic success was obtained in all but 1
patient.
Late angiographic follow-up was obtained in 275 of 355
(77%) eligible patients (median: 278 days, IQR: 226 to 409
days). Either the remaining patients declined this late angio-
graphic follow-up study, or the decision was made by the
attending cardiologist after considering the clinical status.
Baseline characteristics were similar in patients with and
without late angiographic study. At late follow-up, MLD was
arger (1.86  0.7 mm vs. 1.40  0.8 mm, p  0.003) and
ecurrent restenosis rate lower (22% vs. 40%, p  0.008) in
he different-DES group (Table 2). Figure 2 depicts cumu-
lative frequency distribution curves of MLD at all time
points.
Clinical follow-up at 9 months was obtained in 360
patients (99%) and a clinical follow-up longer than 1 year in
349 patients (96%) (median: 771 days, IQR: 488 to 1,144
days). Time to follow-up was similar in both groups. Table 3
summarizes all major adverse clinical events, during hospi-
talization, at 1 year, and at last clinical follow-up. Of
interest, a significant number of events occurred after the
first year. The rate of definitive/probable stent thrombosis at
last follow-up was very low and similar in both groups (2
[0.7%] vs. 1 [1.1%]). Estimates of event-free survival are
presented in Figure 3. On actuarial analysis, the combined
primary clinical endpoint occurred less frequently (23% vs.
35%, p  0.039) in the different-DES group, because of a
lower requirement for TLR.
Crude, adjusted by logistic regression or Cox multivariate
25%75%
363 Pts DES ISR
325 Pts
DES
July ´04
October ´09
Paclitaxel (44%)
Sirolimus (26%) 
Zotarolimus (12%) 
Everolimus (12%)
Others (5%) 
Sirolimus (36%)
Paclitaxel (31%)
Everolimus (31%)
Zotarolimus (2%)
274 Pts
Different DES
51 Pts
Same DES
29 Pts
BA
9 Pts
BMS
11%89%
84% 16%
89 Pts
Other Strategy
Figure 1. The RIBS III Study Flow Chart
BA  balloon angioplasty; BMS  bare-metal stent(s); DES  drug-eluting
stent(s); ISR  in-stent restenosis; Pts  patients.analyses, and propensity sore adjusted (C-index: 0.75)clinical and angiographic results of both strategies are
compared in Figure 4. All outcome estimates favored the
switch strategy. After propensity score adjustment, the
restenosis rate (RR: 0.41, 95% CI: 0.21 to 0.80, p  0.01),
the difference in late MLD (0.41 mm, 95% CI: 0.19 to 0.62,
p  0.001), and the event-free survival (HR: 0.56, 95% CI:
0.33 to 0.96, p  0.038) remained significantly improved in
the different-DES group.
When switch was assessed from a “family perspective” as
a secondary analysis (limus to nonlimus DES and vice
versa), the switch group obtained better late angiographic
(MLD: 1.86  0.8 mm vs. 1.67  0.8 mm, p  0.06;
percentage of diameter stenosis: 29  25% vs. 36  27%,
p  0.04) and clinical (combined clinical endpoint: 17% vs.
25%, p  0.04) outcomes.
Sensitivity analyses (first- vs. second-generation DES and
limus vs. nonlimus DES) failed to detect significant inter-
actions between specific DES types and main clinical
Table 1. Baseline Clinical, Angiographic, and Procedural Characteristics
Characteristic
Different DES
(n  274)
Other Strategy
(n  89) p Value
Age, yrs 66 11 66 10 0.78
Female 78 (29) 19 (21) 0.19
Risk factors
Diabetes mellitus 143 (52) 43 (48) 0.53
Hyperlipidemia 178 (65) 51 (57) 0.19
Hypertension 198 (72) 65 (73) 0.88
Ever smoked 135 (49) 53 (60) 0.09
Clinical features
Unstable angina 129 (47) 44 (50) 0.12
Stable angina 112 (41) 28 (31)
Silent ischemia 33 (12) 17 (19)
Previous myocardial infarction 108 (39) 33 (37) 0.69
Previous bypass surgery 45 (16) 10 (11) 0.24
1 intervention on target
lesion
15 (6) 9 (10) 0.12
Time to restenosis, days 279 (180–576) 334 (245–597) 0.07
Ejection fraction, % 61 14 61 15 0.99
Target artery
Left anterior descending 136 (50) 48 (54) 0.57
Left circumﬂex 45 (16) 16 (18)
Right coronary 79 (29) 22 (25)
Saphenous vein graft 14 (5) 3 (3)
Procedural characteristics
Length of initial stent, mm 22 13 22 12 0.83
Length ﬁnal stent, mm 21 11 18 11 0.07
IVUS/OCT 105 (37) 33 (38) 0.83
Second-/ﬁrst-generation DES 96/178 (35) 11/40 (22) 0.07
Maximal pressure, atm 18 3 17 4 0.29
Balloon/artery ratio 1.33 0.3 1.26 0.3 0.07
Angiographic success 274 (100) 88 (99) 0.25
Values are mean SD, or n/N (%).
DES drug-eluting stent(s); IVUS intravascular ultrasound; OCT optical coherence tomo-graphy.
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732outcome measures. However, limus-DES (restenosis: 21%
vs. 36%, p  0.006) and second-generation DES (resteno-
sis: 16% vs. 31%, p  0.009) provided better late angio-
graphic results than alternative treatment modalities did.
Likewise, in patients receiving DES (different or the same),
late angiographic results were better when limus (restenosis:
21% vs. 32%, p  0.07) or second-generation DES (reste-
nosis rate: 16% vs. 28%, p 0.04) were used. Finally, within
the switch strategy, second-generation DES also obtained
better late angiographic results than first-generation DES
did (restenosis: 15% vs. 26%, p  0.08).
A landmark analysis of the entire population “after” the
first year demonstrated that the appearance of very late
adverse clinical events was similar in both groups, although
numerically lower in the different-DES arm (17% vs. 22%,
p  0.7). Finally, when the different-DES strategy was
Table 2. Angiographic Results
Variable Different DE
Qualitative features
B2-C lesion 161
Mehran class I, II, III, IV 181 (66), 55 (2
Edge-ISR 75
Ostial 34
Calcium 17
Quantitative ﬁndings
Before the procedure (n
Reference vessel diameter, mm 2.41
Minimal lumen diameter, mm 0.77
Stenosis, % of lumen diameter 68
Lesion length, mm 10.1
Diffuse lesions, 10 mm 96
After the procedure (n
Reference vessel diameter, mm 2.41
Minimal lumen diameter, mm 2.26
Stenosis, % of lumen diameter 19
Acute gain, mm 1.61
At follow-up: “in segment” analysis (n
Reference vessel diameter, mm 2.62
Minimal lumen diameter, mm 1.86
Stenosis, % of lumen diameter 29
Restenosis 47
Late loss, mm 0.42
Loss index 0.27
Net gain, mm 1.08
At follow-up: “in lesion” analysis (n
Reference vessel diameter, mm 2.65
Minimal lumen diameter, mm 1.93
Stenosis, % of lumen diameter 28
Restenosis 41
Values are n (%) or mean SD.
DES drug-eluting stent(s); ISR in-stent restenosis.compared exclusively with the same-DES strategy, theswitch strategy also achieved better angiographic results and
a trend to better clinical outcomes (Fig. 5).
In this study, the use of intracoronary diagnostic techniques
(37% of patients) was associated with larger initial angio-
graphic acute gain (1.55  0.6 mm vs. 1.35  0.6 mm, p 
0.01) and MLD at follow-up (1.89  0.8 mm vs. 1.68  0.7
mm, p  0.05) compared with patients not guided by these
techniques, but these results did not translate into a reduction
in target TLR or in the combined clinical endpoint (differ-
ences: p  NS).
Discussion
This study supports the value of a different DES (switch)
strategy in patients suffering from DES ISR. Our study
represents the first large multicenter study where the results
274) Other Strategy (n  89) p Value
55 (62) 0.61
6), 23 (8) 70 (79), 6 (7), 2 (2), 11 (12) 0.01
37 (42) 0.01
17 (19) 0.10
13 (15) 0.01
(n 89)
2.46 0.5 0.45
0.87 0.5 0.06
65 17 0.13
8.1 6 0.01
19 (21) 0.01
(n 89)
2.46 0.5 0.45
2.08 0.6 0.007
22 13 0.04
1.32 0.6 0.001
(n 65)
2.57 0.5 0.47
1.40 0.8 0.003
42 30 0.004
26 (40) 0.008
0.63 0.6 0.02
0.53 1.4 0.18
0.54 0.8 0.001
(n 65)
2.57 0.5 0.22
1.60 0.9 0.01
38 30 0.02
22 (34) 0.016S (n 
(59)
0), 15 (
(27)
(12)
(6)
274)
 0.5
 0.4
 16
 9
(35)
274)
 0.5
 0.5
 10
 0.6
210)
 0.5
 0.7
 24
(22)
 0.6
 0.6
 0.7
210)
 0.5
 0.7
 24
(20)of this strategy have been prospectively evaluated. In addi-
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733tion, the current report provides a uniquely long clinical
follow-up and actually represents the longest clinical and
angiographic follow-up currently available of the different-
DES strategy (9). Our findings suggest that patients treated
with this strategy obtain superior clinical and angiographic
long-term results compared with those seen with alternative
interventions. In particular, the switch strategy achieved a
remarkable improvement in all late angiographic parame-
ters, including MLD, percentage of diameter stenosis, late
loss, net gain, and recurrent restenosis rate. These superior
late angiographic findings translated into improved long-
term clinical outcomes, mainly as the result of a reduction in
the requirement for TLR. Furthermore, the superior clinical
and angiographic results of the different-DES strategy were
maintained despite careful adjustments for potential con-
founders using both classical multivariate models and pro-
pensity score analyses. The consistency of all these indepen-
dent analyses supports the robustness of our findings. In
addition, we also found that when the analysis was restricted
to patients treated with a new DES, the use of a different
DES provided better long-term angiographic results than
the use of the same DES.
In contradistinction to prior studies that only analyzed
the value of first-generation DES (11–16), in the current
study, second-generation DES were used in 33% of patients
treated for DES ISR. Strut thickness and polymer-mediated
inflammatory reaction may act as a stimulus for recurrent
neointimal growth and, therefore, newer-generation DES
might be of particular value in this setting (4). In our study,
the use of second-generation and limus-type DES were
associated with better angiographic outcomes. This might
help to explain the favorable results obtained by the switch
0 
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Figure 2. Cumulative Frequency Distribution Curves of MLD
Cumulative frequency distribution curves of minimal lumen diameters
(MLD) before the procedure (Pre), after intervention (Post) and at late fol-
low-up (FU). Different-drug-eluting-stent group (blue curves), other strat-
egy (red curves) (p  0.003 for difference of means in MLD at follow-up).strategy in our series (11–16). However, due to the post hocnature of these subanalyses and the small sample sizes,
further studies are required to confirm the superiority of
second-generation DES in this setting.
Our findings also suggest that a low, but persistent, event
rate accrues beyond the first year, emphasizing the impor-
tance of maintaining a close long-term clinical surveillance
in these complex patients. We found that recurrences
following treatment of DES ISR might occur after a longer
time interval than those seen in historical series of BMS ISR
(20,21). Finally, our results underscore the safety of repeat
stent implantation in this challenging anatomic scenario.
Indeed, the rate of stent thrombosis in the hetero-DES
strategy at 2-year follow-up was only 0.7%.
Treatment of DES restenosis. Most previous studies consis-
tently demonstrated relatively poor long-term clinical results
in patients treated for DES ISR versus patients with BMS
ISR (7,8). It has been proposed that although DES are
dramatically effective at inhibiting the neointimal proliferative
Table 3. Major Adverse Clinical Events
Event
Different
DES
(n  274)
Other
Strategy
(n  89) p Value HR (95% CI)
Hospital events
Death 0 (0) 0 (0) 1.00 —
Myocardial infarction 1 (0.4) 0 (0) 1.00 —
Target lesion
revascularization
0 (0) 0 (0) 1.00 —
Coronary angioplasty 0 (0) 0 (0) 1.00 —
Coronary surgery 0 (0) 0 (0) 1.00 —
Any major hospital event 1 (0.4) 0 (0) 1.00 —
Events at 1 year
Death 10 (3.7) 6 (6.7) 0.25 0.54 (0.20–1.50)
Cardiac death 6 (2.2) 5 (5.6) 0.13 0.39 (0.12–1.28)
Myocardial infarction 7 (2.6) 1 (1.1) 0.39 2.31 (0.28–18.7)
Target lesion
revascularization
17 (6.3) 12 (13.5) 0.03 0.44 (0.21–0.91)
Coronary angioplasty 16 (5.9) 11 (12.4) 0.05 0.45 (0.21–0.98)
Coronary surgery 2 (0.7) 1 (1.1) 0.73 0.65 (0.06–7.1)
Any major event 28 (10.3) 17 (19.1) 0.04 0.51 (0.28–0.94)
Any major cardiac event 24 (8.9) 17 (19.1) 0.01 0.44 (0.24–0.82)
Events at last follow-up
Death 19 (7.0) 11 (12.4) 0.33 0.68 (0.32–1.46)
Cardiac death 13 (4.8) 8 (9) 0.43 0.68 (0.27–1.71)
Myocardial infarction 10 (3.7) 2 (2.2) 0.46 1.72 (0.38–7.85)
Target lesion
revascularization
37 (13.7) 19 (21.3) 0.08 0.60 (0.34–1.04)
Coronary angioplasty 33 (12.2) 18 (20.2) 0.06 0.57 (0.32–1.01)
Coronary surgery 8 (3.0) 2 (2.2) 0.26 2.83 (0.35–22.7)
Any major event 54 (19.9) 28 (31.5) 0.05 0.60 (0.37–0.99)
Any major cardiac event 48 (17.7) 26 (29.2) 0.04 0.61 (0.37–0.98)
Values are n (%). Patients with 1 event are counted only once for the composite clinical
endpoints, although each event is listed separately in the corresponding category. p values from
Cox analysis.CI confidence interval; DES drug-eluting stent(s); HR hazard ratio; not estimable.
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734response, when they fail to achieve their aim, the elicited
biologic response may actually be more difficult to tackle.
Accordingly, treatment of DES ISR remains a pervasive
technical and clinical challenge (2–4). Some reports suggest
that focal DES ISR may be more likely the consequence of
mechanical or technical factors, whereas diffuse DES ISR
should raise the suspicion of drug failure (2–4). In some
previous studies, this general concept has been empirically used
to select and guide the repeated interventions.
In a pioneer study, Lemos et al. (5) demonstrated that
treatment of patients with sirolimus-eluting stent (SES)
ISR was associated with very high (43%) recurrence rates.
The superiority of additional DES implantation, with a
recurrent restenosis rate of only 29%, over alternative
strategies, was already suggested in this preliminary report.
Kim et al. (6) also suggested that the use of SES, compared
with conventional strategies, for DES ISR was associated
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Figure 3. Kaplan-Meier Estimates of Event-Free Survival
(A) Freedom from major adverse cardiac events (MACE) (cardiac death,
myocardial infarction, and target lesion revascularization [TLR]). (B) Free-
dom from TLR. The number of patients at risk in each time interval is pre-
sented at the bottom. DES  drug-eluting stent(s).with a reduced rate of recurrences. More recently, larger pstudies with long-term clinical follow-up have confirmed
that in patients with DES ISR, repeat DES implantation
provide superior results to those obtained with balloon
angioplasty, even after adjustment for potential confounders
(9,10). Latib et al. (9) and Abe et al. (10) demonstrated that
repeat SES implantation emerged as an independent pre-
dictor of absence of restenosis (9) and TLR (10) at follow-
up. Interestingly, in these studies, the superiority of repeat
DES implantation over balloon angioplasty was also dem-
onstrated in patients with “focal” DES ISR (9,10). Notably,
in all these studies, repeat DES implantation was found to
be very safe and did not increase the risk of stent thrombosis
at late follow-up (10).
Previous studies of the “switch” strategy. On theoretical
rounds, the use of DES is highly appealing in patients with
ES ISR considering, first, that restenting guarantees
ptimal early angiographic results and, second, the powerful
ntirestenosis properties of DES (7–16). Likewise, in this
cenario, the rationale for a different-DES strategy stems
rom the concept of drug failure at an individual patient
evel. In fact, some previous studies have demonstrated that
enetic factors may explain individual resistance to either
irolimus or paclitaxel (17–19). Considering the different
echanisms of action of drugs currently available in DES,
he idea of trying a new drug has been considered as
articularly attractive to tackle DES failures. Likewise,
ypersensitivity reactions to metals (nickel and molybde-
um) (25), different alloys, and even to specific durable
olymers may elicit untoward proliferative responses (2–4).
ll these problems could be exacerbated if the same DES is
sed to manage recurrences but might be prevented using a
ifferent DES.
Five small observational and retrospective studies (11–15)
ave focused on the analysis of a switch strategy compared
ith other treatment modalities. Although highly hetero-
eneous in nature and design, these studies lumped together
87 patients with DES ISR (279 treated with the same
ES and 208 with different DES). Most of these studies
eported similar clinical and angiographic results with the 2
trategies; although, numerically, the rate of major adverse
vents always tended to be lower in the switch strategy
11–15). Only Mishkel et al. (13) explicitly suggested a
otential benefit of the switch modality. At 1 year, the rate
f TLR was 19% with a different DES; 29% with the same
ES; and 37% after cutting-balloon, BMS, or brachyther-
py. All these studies reported retrospective analyses of
trategies selected by the investigators, baseline characteris-
ics differed among therapeutic modalities, and no attempt
as made to adjust for potential confounders (11–15).
ndeed, most investigators favored the switch strategy in
atients with diffuse DES ISR, whereas the same-DES
trategy was more frequently used in focal DES ISR (9).
nterestingly, in our study, the switch strategy also encom-
assed longer lesions. Furthermore, in these studies, the
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735number of patients included was small; follow-up duration
was limited; late angiographic evaluation was not systemat-
ically obtained; and treatment modalities were highly di-
verse (11–15). Therefore, overall results do not allow draw-
ing definitive conclusions on the potential value of the
switch strategy.
Recently, Mehilli et al. (16) reported the ISAR-DESIRE-2
(Intracoronary Stenting and Angiographic Results: Drug Elut-
ing Stents for In-Stent Restenosis 2) randomized study. This
trial allocated 450 patients with SES ISR to either repeat
SES implantation (n  225) or paclitaxel-eluting stent
PES) implantation (n  225). Late lumen loss, MLD at
follow-up (1.93 0.73 mm vs. 1.94 0.67 mm) and binary
restenosis rate were similar following SES and PES. TVR
rates were also similar in both arms. However, two-thirds of
enrolled patients presented ISR of the polymer-free ISAR-
SES, a stent not widely available (16). Moreover, the
antiproliferative efficacy of SES and PES is different (16).
Previous reports by the same group demonstrated that SES
were more effective than PES to inhibit tissue proliferation
(26). Therefore, it remains possible that the equivalent
MLD 
RESTENOSIS 
MAE 
MACE 
TLR 
Other Strategy Better  Differen
0 1 
 (mm) 
-0.5 0 0.5 -1 
Different DES Better Other Stra
Figure 4. Comparison of Main Clinical and Angiographic Outcome Measure
Comparisons are presented as crude estimates, adjusted (Adj.) (logistic regress
HR  hazard ratio; RR  relative risk; other abbreviations as in Figures 1 to 3.results obtained in the 2 arms were largely driven by the use sof a less effective DES (PES) in the switch arm. Clinical and
angiographic equipoise might have been the result of a
superior ability of SES to suppress neointimal proliferation
being counterbalanced by a potential resistance to sirolimus
in patients suffering from SES ISR. Accordingly, the
question regarding the potential value of a different DES
strategy in patients with DES ISR remains open.
Study limitations. First, a wide array of DES with ISR were
nalyzed in this study, and patients were treated with diverse
trategies (Fig. 1). Even in patients undergoing the recom-
ended switch strategy, different DES were selected. This
eterogeneity provides multiple small treatment subgroups,
recluding a comprehensive analysis of the individual effec-
iveness of particular DES. However, this reinforces the
rimary hypothesis of the study, namely that the different-
ES strategy (as a proof of concept) provides superior
esults than alternative treatment modalities do. This was
lso supported by the parallel findings of the switch strategy
nalyzed as a family strategy. Likewise, the number of
atients treated with a same-DES strategy was limited, so
hen this strategy alone was used as the comparator,
Difference of Means 
Crude  0.37 (0.15-0.59) p=0.003 
Adj.  0.41 (0.21-0.62) p=0.001 
Adj. Propensity Score 0.41 (0.19-0.62) p=0.001 
 Better 
HR (95%CI) 
Crude  0.60 (0.37-0.99) p=0.05 
Adj.  0.61 (0.38-0.99) p=0.049 
Adj. Propensity Score 0.63 (0.39-1.01) p=0.06 
Crude  0.61 (0.37-0.98) p=0.04 
Adj.  0.57 (0.34-0.96) p=0.04 
Adj. Propensity Score 0.56 (0.33-0.96) p=0.038 
Crude  0.60 (0.34-1.04) p=0.08 
Adj.  0.54 (0.30-0.98) p=0.043 
Adj. Propensity Score 0.63 (0.39-1.01) p=0.06 
Crude  0.56 (0.38-0.83) p=0.005 
Adj.  0.40 (0.20-0.78) p=0.008 
Adj. Propensity Score 0.41 (0.21-0.80) p=0.01 
RR (95%CI) 
2 
1 
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Cox analysis), and propensity score adjusted. MAE  major adverse events;t DES
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ion ortatistically significant superior results were only found in
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736angiographic outcomes. Second, this was a nonrandomized
study and therefore has all the inherent limitations of
observational studies. Precise patient-level reasons for not
selecting the recommended strategy could not be fully
elucidated. Thus, conventional and propensity score multi-
variate adjustments were used to address this issue providing
consistent results, further suggesting the superiority of the
switch approach. Nevertheless, the possibility that residual
unmeasured confounders would have affected our findings
cannot be discarded. In addition, the number of events of
some outcome measures was relatively low and the potential
for overfitting in some multivariate models must be consid-
ered. Third, angiographic follow-up (77%) was incomplete.
Accordingly, our results should be only considered as
hypothesis generating. Further studies with larger series of
patients are warranted to definitively confirm these findings.
Fourth, although intravascular ultrasound is a valuable
technique in patients with ISR, this tool was not systemat-
ically used in the current series. Finally, the value of drug-
eluting balloons has recently been demonstrated in patients
with DES (27), yet these balloons were not available at the
RESTENOSIS 
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Figure 5. Main Outcome Measures Compared Only Between the Different-D
Outcome measures are presented as crude estimates, adjusted with logistic regrestime of this study.Conclusions
In patients with DES ISR, the use of a different DES
provides superior long-term clinical and angiographic re-
sults compared with other therapeutic modalities.
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APPENDIX
For a list of participating university hospitals, please see the online version
of this article.
